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Oxysterol analogs that modulate NMDA receptor function are candidates for therapeutic
development to treat neuropsychiatric disorders. However, the cellular actions of
these compounds are still unclear. For instance, how these compounds are
compartmentalized or trafficked in neurons is unknown. In this study, we utilized a
chemical biology approach combining photolabeling and click chemistry. We introduce
a biologically active oxysterol analog that contains: (1) a diazirine group, allowing
for the permanent labeling of cellular targets, and (2) an alkyne group, allowing
for subsequent in situ visualization using Cu2+ catalyzed cycloaddition of an azide-
conjugated fluorophore. The physiological properties of this analog at NMDA receptors
resemble those of other oxysterols, including occlusion with other oxysterol-like
compounds. Fluorescent imaging reveals that the analog accumulates diffusely in the
cytoplasm of neurons through an energy-independent mechanism. Overall, this work
introduces a novel chemical biology approach to investigate oxysterol actions and
introduces a tool useful for further cell biological and biochemical studies of oxysterols.
Keywords: NMDA receptor, oxysterol, photolabel, click chemistry, modulation
INTRODUCTION
N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels that play important
roles in neurobiological function. Normal NMDAR function is associated with synaptic plasticity
important for encoding new memories, but abnormal NMDAR function is implicated in a
multitude of neuropsychiatric defects, including depression, autism, schizophrenia, Alzheimer’s
disease, and epilepsy. Therefore, these receptors represent important therapeutic targets for
many CNS disorders, and both negative and positive regulators have potential roles. Oxysterol
compounds, analogs of the natural cholesterol metabolite 24S-hydroxycholesterol (24S-HC),
are pharmacologically efficacious positive allosteric modulators of NMDARs (Paul et al., 2013;
Linsenbardt et al., 2014; Warikoo et al., 2018). 24S-HC is the most abundant cholesterol oxidation
product in the brain, reaching concentrations that modulate NMDAR function (Sun et al.,
2016a). Synthetic and natural oxysterols are still being characterized, but oxysterol analogs may
hold promise in the treatment of neuropsychiatric disease (Sun et al., 2016b; Warikoo et al.,
2018). Pharmacological actions of lipophilic agents like oxysterols can be affected by cellular
compartmentalization, which may serve as a source or a sink of drug actions, depending on
circumstances (Li et al., 2007; Jiang et al., 2016). However, the mechanisms by which oxysterols
are trafficked or compartmentalized in neurons are unknown.
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A limitation to understanding these mechanisms is the lack
of methods to visualize the cellular distribution of oxysterols. To
reduce this barrier, we introduce a novel analog of 24S-HC, MQ-
182. This analog contains a diazirine group, allowing for in situ
photolabeling, and an alkyne group, permitting click chemistry.
The approach of combining click chemistry and photolabeling
has recently emerged as a tool for studying cyto-localization
(Hofmann et al., 2014; Peyrot et al., 2014; Jao et al., 2015), and
our group has previously used this approach to characterize the
cellular actions of GABA-active neurosteroid analogs (Jiang et al.,
2016). These analogs may also prove useful for identifying sites
on NMDARs and other targets for steroid and oxysterol binding
(Chen et al., 2012, 2014; Budelier et al., 2017). In this study, we
introduce a click photolabeling analog MQ-182 to probe cellular
compartmentalization, thereby informing our understanding of
oxysterol uptake and accumulation.
Here, we characterize the pharmacological effects, using an
in vitro electrophysiological approach, and cellular accumulation
of MQ-182 in cultured hippocampal neurons. Chemical
modification required for visualization may alter the behavior of
an analog, so we assayed the properties of MQ-182 at NMDARs
and several off-target candidates. We demonstrate that MQ-182
is a potent potentiator of NMDARs, increases the open channel
probability of the NMDAR, and occludes the effect of another
oxysterol-like modulator but not a sulfated steroid modulator.
These observations suggest that the analog is biologically
active and modulates NMDARs through an oxysterol-like
mechanism. MQ-182 accumulates diffusely in the cytoplasm
of neurons, suggesting the possibility of additional targets. At
high concentrations, MQ-182 unexpectedly potentiated GABA
release, but at lower concentrations, its effects were confined to
NMDAR modulation.
Our work introduces a synthetic analog that retains
electrophysiological characteristics of oxysterols while enabling
visualization of drug localization. The intracellular accumulation
of this probe may be relevant to cellular actions of oxysterols
aside from an effect on surface NMDARs, although our work
revealed only limited evidence for off target effects at high
concentrations. Our approach of tandem photolabeling and click
chemistry offers the promise of biochemical studies to identify
oxysterol sites on NMDARs.
MATERIALS AND METHODS
Hippocampal Cell Culture
Cell cultures were prepared and maintained as described
previously (Mennerick et al., 1995). In brief, hippocampal
and cortical tissue was harvested from postnatal 1–3 days old
Sprague–Dawley rats of both sexes. This study was carried out in
accordance with the recommendations of the National Institutes
of Health guidelines for animal care and use. The protocol was
approved by the Washington University Institutional Animal
Care and Use Committee.
Murine neuro-2a (N2a; ATCC #CCL-131) cells were cultured
in Dulbecco’s Modified Eagle’s medium (DMEM) with 10%
FBS, 2 mM glutamine, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin in 5% CO2 and 95% air. Cells were transiently
transfected with GluN1a (0.34 µg) and GluN2A-GluN2D
subunits as previously described (Warikoo et al., 2018).
Electrophysiology
Whole-cell electrophysiological recordings were performed on
the stage of an Eclipse TE2000-S inverted microscope. Data
were collected using with a Multiclamp 700B amplifier and
Digidata 1440 data acquisition board (Molecular Devices) using
pClamp 10 software. During experiments in which GABAergic
and glutamatergic postsynaptic currents (PSCs) were studied, the
intracellular pipette solution contained the following (in mM):
130 CsCl, 4 NaCl, 10 HEPES, 5 EGTA, and 0.5 CaCl2. The pH
was adjusted to 7.25 with NaOH. In all other experiments, the
solution contained 130 CsMeSO4 instead of CsCl.
Extracellular solution during whole-cell patch clamp
recordings typically contained 138 mM NaCl, 4 mM KCl, 10 mM
HEPES, 10 mM glucose, 2 mM CaCl2, 1 mM MgCl2, 1 µM
NBQX, and 10 µM gabazine. During experiments in which
GABAergic PSCs were recorded from neurons, 25 µM D-APV
was used instead of 10 µM gabazine, and during experiments in
which AMPAR PSCs were recorded, 25 µM D-APV was used
instead of 1 µM NBQX. During experiments in which miniature
postsynaptic currents (mPSCs) were recorded, 0.25 µM TTX was
added. Antagonists were omitted in recordings from transfected
N2a cells.
Whole-cell recording pipettes were pulled from borosilicate
glass capillary tubes (World Precision Instruments) and had
final open-tip resistances of 3–6 M. Neurons were clamped
at −70 mV unless otherwise stated. When drug delivery was
performed, solutions were dispensed by a gravity-driven local
perfusion system from a common tip with exchange time of
∼100 ms.
In situ Click Chemistry and Imaging
Cell cultures were incubated with 10 µM MQ-182 in saline
containing (in mM): NaCl (138), KCl (4), CaCl2 (2), MgCl2
(1), glucose (10), HEPES (10), pH 7.25 with NaOH. Cells were
exposed to 365 nm light from a 0.15A Blak-Ray lamp for
15 min. Afterward, cells were fixed for click processing with
4% paraformaldehyde + 0.05% glutaraldehyde in phosphate-
buffered saline (PBS) for 10 min. In some experiments, cells
were fixed for 10 min prior to incubation in MQ-182 with
15 min ultraviolet (UV) illumination. After rinsing with PBS,
the click reaction proceeded by incubating fixed cells with 1 µM
azide-Alexa Fluor 488 (Molecular Probes), a click reagent for
fluorescence visualization, in 100 µM Tris[(1-benzyl-1H-1,2,3-
triazol-4-yl)methyl]amine in DMSO, 2 mM sodium ascorbate,
and 1 mM CuSO4 for 1 h in the dark. For combined in situ click
and immunostaining, protocols were as described previously
(Jiang et al., 2016). Briefly, prior to in situ click labeling, cells
were incubated in primary antibodies against PDI (1:2000) and
giantin (1:2000), for 2 h, followed by labeled secondary antibody
(AlexaFluor 647, 1:500) for 1 h.
Cells were imaged on a Nikon Eclipse TE2000-S microscope
equipped with a C1 laser scanning confocal attachment. For each
field, a z-stack image was acquired, and a maximum intensity
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FIGURE 1 | MQ-182 is a potent positive allosteric modulator of NMDARs.
(A) Natta projection structure of MQ-182. (B) Effect of MQ-182 on NMDAR
currents. Cultured primary hippocampal neurons were incubated in 10 µM
MQ-182 and 20 µM D-serine in the nominal absence of Mg2+ for 30 s,
followed by 5 s NMDA application. The horizontal black bar represents the
application of NMDA (10 µM, 5 s) and the red bar represents the application
of MQ-182 (10 µM, 45 s). Pre-application was for 30 s before co-application
with NMDA. (C) The normalized change in NMDAR current magnitude is
plotted. The red symbol denotes the mean potentiation. Asterisk represents a
significant increase in NMDAR current magnitude (p = 0.00020, n = 15,
one-sample t-test).
z-projection was created from the slices wherein the cells of
interest were visible. In order to assess peri-membrane and
intracellular fluorescence, region of interest (ROI) lines at 10
pixel thickness were drawn through the cell from left to right,
excluding the nucleus. Fluorescence intensity was measured
along the line, and fluorescence values were divided into three
equal parts. Peak fluorescence value of the first third of pixels
above background fluorescence was taken as the intensity of the
left cell membrane, average fluorescence of the next third of pixels
was taken as the intracellular fluorescence, and peak fluorescence
of the final third of pixels was taken as the fluorescence of the
right cell membrane. In the case of peak membrane fluorescence,
values were validated by eye to occur near the edge of the
cell. Quantitation of confocal images was performed using
the Fiji distribution of ImageJ imaging software. Fluorescence
intensity from individual experiments was log10 transformed
FIGURE 2 | MQ-182 is effective at sub-micromolar concentrations.
(A) Increasing potentiation of NMDAR currents (10 µM NMDA, 20 µM
D-serine) by increasing concentrations of MQ-182. Concentrations used were
0.1 nM (red), 1 nM (blue), 0.1 µM (green), 1 µM (purple), pre-applied before
agonist application. Dotted line represents magnitude of baseline NMDA
current. (B) Potentiation values were fit with the Hill equation (solid line). EC50
of MQ-182 was estimated at 1.2 nM (n = 14). Symbols are color coded as
in (A).
to better meet the assumption of data normality of parametric
tests. Analysis of variance or linear mixed models using cluster
(experiment) as a separate covariate were performed to test for
fluorescence differences among conditions.
Data
Data were analyzed and plotted using Clampfit 10 (Molecular
Devices), Excel 2011 (Microsoft), Prism 6 (GraphPad), SAS
9.4 (SAS Institute Inc.), and ImageJ software. Unless otherwise
stated, summary data in figures and text are given as
mean ± SEM. Statistical tests for comparison of means are
described in the figure legends for clarity. Comparisons were
corrected for multiple comparisons as described in the legends.
Statistical significance was defined as a corrected p-value < 0.05.
The reported n refers to the number of neurons in each group
within a particular experiment. For imaging experiments, the
number of independent experiments is also given.
Materials
The synthesis of MQ-182 is reported in the Supplementary
Materials. D-APV, NBQX, and TTX were obtained from Tocris
Biosciences, and all materials without an identified supplier were
obtained from Sigma-Aldrich. Antibody species and sources were
as follows: giantin (Covance Research Products Inc catalog PRB-
114C-200, RRID:AB_10063713), PDI (Abcam catalog ab2792,
RRID:AB_303304). SGE-201 was a gift from Sage Therapeutics.
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FIGURE 3 | MQ-182 accelerates rate of memantine block reversal, suggesting
that it increases the open-channel probability of the NMDAR. (A) Cells were
challenged with 10 µM NMDA (horizontal blue bar, 40 s) and 10 µM
memantine (MEM, horizontal red bar, 15 s). (B) Cells were pre-incubated in
10 µM MQ-182 for >5 min and challenged with the same protocol as
described in (A). (C) The current relaxation upon memantine removal (red
arrows in A) was fitted with a monoexponential curve. Time constant values (τ)
from these fits are plotted. Asterisk represents a decrease in tau (p = 0.0017,
n = 19 for -MQ-182, n = 18 for +MQ-182, Student’s unpaired t-test).
RESULTS
MQ-182 Is a Positive Allosteric
Modulator at NMDARs
The structure of MQ-182 is shown in Figure 1A. In the
sterol side chain, the compound contains a diazirine group,
enabling photoattachment to lipids and proteins in the presence
of 365 nm UV light, and an alkyne group, enabling bio-
orthogonal copper catalyzed azide-alkyne Huisgen cycloaddition.
Chemical modifications can alter the physiological behavior of
a compound, so we assayed MQ-182 at NMDARs to determine
if it retained oxysterol-like activity. In dissociated cultures of
rat hippocampal neurons, we explored the effect of MQ-182 on
currents evoked by exogenous NMDA (Figures 1B,C). MQ-182
(10 µM) pre-application caused nearly a doubling of the response
to 10 µM NMDA, consistent with the actions of naturally
occurring oxysterols (Paul et al., 2013). In a concentration-
response study, MQ-182 potentiated NMDAR currents at low
nanomolar concentrations, with an EC50 estimate of 1.2 nM
(Figure 2). This is ∼600- and 60-fold more potent than 24S-
HC and SGE-201, a natural and synthetic oxysterol analog,
respectively (Paul et al., 2013).
Oxysterols increase NMDAR channel open probability,
resulting in altered kinetics of dissociation of open-channel
trapping blockers such as memantine and ketamine (Emnett
et al., 2015), which require channel opening for dissociation. To
characterize further MQ-182’s potentiation of NMDAR currents,
we explored its effects on the rate of open-channel blocker
dissociation (Figure 3). After obtaining a steady-state NMDAR
current, we co-applied memantine, which rapidly decreased
NMDAR current. When the current reached a new steady state,
we removed memantine in the continued presence of NMDA and
evaluated the kinetics of re-emergence of current to its original
magnitude. In the presence of MQ-182, the time constant of
current re-emergence was decreased relative to different cells in
the absence of MQ-182 (Figure 3C). This change suggests that
MQ-182 increased the open-channel probability of the NMDAR,
thereby accelerating the reversal of memantine’s actions.
Increased probability of channel opening characterizes several
classes of positive NMDAR modulators (Popescu, 2005). The
actions of oxysterol-like modulators can be distinguished from
others by occlusion assays (Linsenbardt et al., 2014). We
tested pharmacological occlusion by pre-incubating neurons for
>5 min in 10 µM MQ-182 and then challenging with NMDA
and another positive allosteric modulator (Figure 4). SGE-201,
a synthetic oxysterol analog, is a potent potentiator of the
NMDAR, and we would expect a decrease of its potentiation
if MQ-182 interacts with the oxysterol binding site. Indeed,
MQ-182 incubation decreased SGE-201 potentiation, but not
pregnenolone sulfate (PS) potentiation (Figures 4C,D). We note
that the occlusion between SGE-201 and MQ-182 was incomplete
at the concentrations tested (Figure 4). This could suggest
additional mechanisms, but the data suggest at least a partially
shared mechanism of action between MQ-182 and SGE-201,
supporting an oxysterol-like mechanism.
Another distinguishing characteristic of oxysterol-like
potentiation vs. PS-like potentiation is subunit selectivity.
Oxysterols potentiate GluN2C and GluN2D-containing
NMDARs (Paul et al., 2013), but PS does not (Horak et al.,
2006). Consistent with the idea that MQ-182 is an oxysterol-
like modulator, we found that 10 µM MQ-182 potentiated
recombinant receptors containing GluN2A, B, C, or D
(Figures 4E–G).
We observed in pilot experiments that potentiation took
∼30 s to reach maximal effect, and was poorly reversible once
established. It is possible that MQ-182’s slow kinetics are due to
slow dissociation from the NMDAR, or from slow departitioning
from the plasma membrane bilayer, from which it likely accesses
the NMDAR. If the membrane-associated compound is in
rapid equilibrium with the receptor, extracellularly applied
γ-cyclodextrin (γ-CDX) may be able to complex and sequester
MQ-182 (Shu et al., 2007), leading to accelerated offset of MQ-
182 effects. To investigate this, we potentiated NMDAR currents
with two 30 s pre-applications of 0.5 µM MQ-182, followed
by co-application with NMDA (Figure 5A). We used 0.5 µM
MQ-182 instead of 10 µM to avoid saturation. After assuring
maximum potentiation, cells were washed with 30 s saline before
re-application of NMDA alone. Saline wash had little effect on
the potentiated NMDAR current, confirming slow reversibility
(Figure 5B). Cells were then challenged with γ-CDX (500 µM),
followed by re-application of NMDA. γ-CDX application did not
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FIGURE 4 | MQ-182 exhibits characteristics of oxysterol potentiation rather than sulfated steroid potentiation. (A–D) Occlusion studies. (A,B) Representative traces
of occlusion protocol. Cells were preincubated in MQ-182 for >5 min and then challenged with 10 µM NMDA (5 s, horizontal black bar) and 0.2 µM SGE-201 or
50 µM PS (45 s pre-application). Each pair of black and red traces comes from a different cell. (C,D) Summary data of (A,B). Although SGE-201’s potentiation of
NMDARs was decreased by pre-incubation in MQ-182, PS’s potentiation was not (p = 0.78, n = 17 for -MQ-182, n = 15 for +MQ-182). Asterisk represents
p = 0.0013, n = 8 (potentiated response vs. baseline), Student’s unpaired t-test. (E–G) Tests of subunit selectivity. (E,F) N2A cells expressing human GluN1a and
one of four GluN2 subunits (A–D) were incubated in 10 µM MQ-182 and 20 µM D-serine in the nominal absence of Mg2+ for 30 s, followed by 5 s NMDA
application. Representative traces are shown for two cells in (E,F). (G) Subunits containing each of the four GluN2 subunits (GluN2A-D) showed potentiation by
MQ-182. Dotted line represents magnitude of baseline NMDA current. Asterisks represent a significant increase in NMDAR current magnitude (asterisks: GluN2A,
p = 0.00020, n = 8; GluN2B, p = 0.00070, n = 12; GluN2C, p = 0.0032, n = 12; GluN2D, p = 0.0053, n = 8; one-sample paired t-test).
reduce potentiated NMDAR current. This suggests one of at least
three possibilities: (1) that MQ-182 rapidly dissociates from the
NMDAR but resides in the membrane at a depth inaccessible
to γ-CDX, (2) that MQ-182 binds to the receptor with a slow
dissociation rate, or (3) that MQ-182 does not easily complex
with γ-CDX. This latter possibility has been shown for the natural
oxysterol 24S-HC (Paul et al., 2013).
To experimentally test the latter possibility, we pre-mixed
MQ-182 with γ-CDX (Figure 5C). If MQ-182 does not form
inclusion complexes with γ-CDX, then we would expect MQ-
182 pre-mixed with γ-CDX to exhibit reduced potentiation
compared with MQ-182 alone, since γ-CDX-complexed MQ-182
would presumably not be active. Indeed, we observed that MQ-
182 potentiation was reduced compared to a control MQ-182
solution containing no γ-CDX (Figure 5D). These results suggest
that MQ-182 binds avidly to the NMDAR or partitions into the
membrane at a position inaccessible to γ-CDX. These alternatives
are considered further in the Discussion.
MQ-182 Intracellular Accumulation
After investigating the pharmacological behavior of MQ-182,
we performed in situ visualization of the analog using tandem
photolabeling and click chemistry (Figure 6). Cells were
incubated in 10 µM MQ-182 with or without UV light exposure,
followed by paraformaldehyde fixation. Because diazirine
photolabeling covalently attaches compounds to nearby proteins
and lipids, this protocol permanently labels intracellular sites of
steroid accumulation with untagged MQ-182. Following fixation
and membrane permeabilization, we used azide-conjugated
Alexa Fluor 488 for click-mediated fluorescence visualization.
Figure 6B shows that both UV light and the presence of MQ-
182 are required for strong labeling of hippocampal neurons,
confirming the effectiveness of the in situ click reaction and the
in situ photolabeling. We also observed labeling without UV
illumination, indicating strong intracellular retention even in
the absence of photolabeling (Figures 6A,B). The pattern of
accumulation was mainly somatic with little neuritic labeling,
consistent with previous studies using fluorescent neurosteroid
analogs (Jiang et al., 2016). MQ-182 accumulated diffusely
in the cytoplasm of neurons, with minor differences between
intracellular and peri-membrane fluorescence (Figure 6C). The
lack of plasma-membrane enrichment was also evident in co-
labeling experiments in which Golgi was labeled with anti-giantin
antibody, and endoplasmic reticulum was labeled with anti-PDI
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FIGURE 5 | The actions of MQ-182 exhibit weak reversibility. (A) Cells were challenged with 10 µM NMDA to establish baseline NMDAR currents. Cells were then
challenged with repeated 30 s pre-applications of 0.5 µM MQ-182, a sub-saturating concentration (red traces). Following 60 s total MQ-182 exposure, cells were
challenged with 30 s saline wash (black trace). Cells were then challenged with γ-CDX wash (30 s, 500 µM) before application of NMDA in the absence of γ-CDX.
(B) Summary plot. The Friedman test, a modified one-way repeated measures ANOVA for non-parametric data, revealed no interaction between the treatment
condition (MQ-182, saline wash, γ-CDX wash) and magnitude of NMDAR current (p = 0.37, n = 5). Post hoc Dunn’s multiple comparisons tests revealed no
differences between the MQ-182 and saline wash conditions (p = 0.42, n = 5), or between the MQ-182 and γ-CDX wash conditions (p = 0.23, n = 5). (C) Test of
CDX/MQ-182 interaction. Cells were first challenged with 10 µM NMDA (black trace), and baseline NMDAR currents were established. Next, they were challenged
with a solution of 0.5 µM MQ-182, pre-mixed with 500 µM γ-CDX (red trace). Finally, they were challenged with 0.5 µM MQ-182 without γ-CDX (light blue trace).
(D) Comparison of potentiation by MQ-182 alone and MQ-182 pre-mixed with γ-CDX. Dotted line represents magnitude of baseline NMDA current. A Wilcoxon
matched-pairs signed rank test showed a difference between conditions. Asterisk represents an increase in potentiation from the MQ-182 + γ-CDX condition to the
MQ-182 alone condition (p = 0.0078, n = 8). Dashed line represents baseline NMDA current.
antibody (Figure 6D). Neither antibody showed significant
co-localization (Figures 6E,F), suggesting indiscriminate
intracellular accumulation by MQ-182. This pattern of
accumulation differs from that of other neurosteroid analogs,
with many exhibiting Golgi-selective or membrane-selective
accumulation (Peyrot et al., 2014; Jiang et al., 2016).
To gain insight into factors that might contribute to MQ-182’s
diffuse pattern of accumulation and retention, we investigated
whether the uptake of MQ-182 was energy dependent (Figure 7).
In this experiment, we compared fixed neurons, which cannot
use ATP-dependent pathways, with live neurons. Interestingly,
there was little change in either the intensity of labeling or
the pattern of accumulation (Figure 7B). We conclude that
energy-dependent pathways do not need to be invoked in the
intracellular accumulation of MQ-182.
The diffuse pattern of accumulation also led us to wonder
whether MQ-182 might have neuronal targets besides NMDARs.
In order to investigate possible off-target effects, we recorded
pooled spontaneous AMPA receptor (AMPAR) spontaneous
EPSCs (sEPSCs) and GABAA receptor (GABAAR) sIPSCs from
multineuron cultures. Because PSCs often occur in bursts,
which precluded accurate measurement of event frequency,
we integrated the total negative-going current as a measure
of aggregated presynaptic activity and postsynaptic effects.
We observed in pilot experiments that at 10 µM, MQ-182
increased the total charge of sPSCs. Because some steroid-like
neuromodulators interact with GABAARs, we hypothesized that
MQ-182 increased the frequency of sPSCs by blocking network
inhibition. However, the effect did not result from postsynaptic
disinhibition because 10 µM MQ-182, in contrast to PS, failed to
affect exogenous GABA responses (Figure 8).
To determine whether effects on PSCs occur at both
excitatory and inhibitory synapses, we pharmacologically isolated
AMPAR transmission and GABAAR transmission individually
and challenged cells with 10 µM MQ-182. We found that while
GABAAR sIPSC charge was potentiated, AMPAR sEPSC charge
was not (Figures 9A,B).
These effects could be mediated by increased interneuron
firing or by direct effects on synaptic function. To test whether the
effect of 10µM MQ-182 on spontaneous transmission arose from
direct action on synaptic targets, we examined mPSCs. MQ-182
(10 µM) increased both frequency and amplitude of GABAAR
mIPSCs but did not affect AMPAR mEPSCs (Figures 9C,D).
These results suggest complex actions of 10 µM MQ-182
involving presynaptic targets at inhibitory synapses.
To determine if these off-target effects are preserved at lower
concentrations of MQ-182 at which NMDAR modulation is
observed, we tested 1µM MQ-182 on sIPSCs. We did not observe
a potentiation in charge (Figure 9E), suggesting that MQ-182’s
actions at GABA synapses are not observed at concentrations
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FIGURE 6 | Diffuse cytoplasmic labeling of a hippocampal neuron by MQ-182. (A) A hippocampal culture was incubated in 10 µM MQ-182, exposed to 365 nM UV
irradiation for 15 min, and processed for click cyto-fluorescence using azide-conjugated AlexaFluor 488. Panels are labeled with the experimental conditions. Scale
bar: 15 µm. (B) Comparison of MQ-182 +UV, MQ-182 -UV, and no drug +UV conditions. A two-way ANOVA with experimental condition and day of experiment
(represented as separate colored symbols) as the two independent variables revealed a significant difference in fluorescence between experimental conditions
[p < 1.0 × 10-15, n = 35, F(2,75) = 523.3]. There was also a significant difference between experiment [p = 6.2 × 10-12, n = 35, F(6,75) = 16.34] and an interaction
between experimental condition and experiment [p < 1.0 × 10-15, n = 35, F(12,75) = 16.44], suggesting differences in the degree of overall fluorescence in different
experimental runs. Post hoc Bonferroni corrected Student’s unpaired t-tests revealed significant differences between the MQ-182 +UV and MQ-182 -UV conditions
[p = 1.1 × 10-7, n = 35, bottom asterisk) and between the MQ-182 +UV and the no drug +UV conditions (p < 1.0 × 10-15, n = 35, top asterisk). (C) Comparison of
peri-membrane and intracellular fluorescence in the MQ-182 +UV condition. Membrane (L) refers to the left side of the cell membrane as viewed in the z-projection,
while Membrane (R) refers to the right side. A two-way ANOVA suggested differences between intracellular and peri-membrane fluorescence [p = 0.0048, n = 35,
F(2, 56) = 5.88]. Post hoc Bonferroni corrected Student’s unpaired t-tests revealed differences between the intracellular and left membrane locations (p = 0.019,
n = 35, left asterisk) and between the intracellular and right membrane locations (p = 0.0046, n = 35, right asterisk), suggesting somewhat stronger intracellular
fluorescence. (D,E) Combined click cyto-fluorescence with immunofluorescence for PDI, an endoplasmic reticulum marker, and giantin, a Golgi-specific protein,
show little co-labeling. Scale bar: 2.14 µm. Line scans are shown in (F,G).
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FIGURE 7 | MQ-182 accumulation in fixed neurons. (A) Neurons were
incubated with 10 µM MQ-182 and exposed to the UV irradiation protocol
while either alive or fixed in 4% paraformaldehyde. Live cells were then fixed in
paraformaldehyde, and all cells were processed for click cyto-fluorescence as
previously described. Panels depict live and fixed cells in the MQ-182 +UV
condition. Scale bar: 5 µm. (B) Summary of labeling intensity. A linear mixed
model revealed no difference in fluorescence between the live and fixed
conditions when adjusting for day of experiment and presence of drug/UV
[p = 0.1192, n = 20, F(1,110) = 2.47]. Each independent experiment is
denoted with a different color symbol.
still near maximum for NMDAR effects. Although 1 µM MQ-
182 did not effect a reliable potentiation of GABAAR sIPSC
charge, it increased the decay time constant of NMDAR sEPSCs
(Figure 10), confirming selective modulation of NMDARS at this
concentration.
DISCUSSION
Oxysterol analogs are candidates for the treatment of
neuropsychiatric disorders (Sun et al., 2016b; Warikoo et al.,
2018). To successfully develop these compounds as therapeutics,
we must find tools to explore their cellular fate. However, the
methods available for the microscopic imaging of sterols are
few (Jao et al., 2015). Here, we studied the pharmacological
properties and cellular accumulation of a visualizable oxysterol
analog. This analog retains physiological activity at NMDARs
and permits tandem photolabeling and click chemistry, allowing
us to permanently label sites of accumulation, followed by
visualization. The studies demonstrate potent, long-lived actions
FIGURE 8 | MQ-182 does not potentiate responses to exogenous GABA.
(A) Hippocampal cultures were incubated in 10 µM MQ-182, 25 µM D-APV
and 1 µM NBQX for 30 s, followed by 20 s application of 5 µM GABA (black).
Baseline GABAAR currents were established. Cells were then challenged with
30 s pre-incubation of MQ-182, followed by 20 s application of GABA
co-applied with MQ-182 (green). Finally, they were challenged with 20 s
application of GABA co-applied with 10 µM PS (blue). Representative traces
are shown, with peak and steady state areas of the trace circled with colors
used for ensuing summaries. (B) Summary of effect of drugs on peak and
steady-state GABA current. A two-way repeated measures ANOVA indicated
a main effect of drug for PS (p = 0.009) but not for MQ-182 (p = 0.70). For PS
there was also a significant interaction between drug and time (p = 0.009),
indicating a more prominent effect on steady-state current, as expected from
the mechanism of PS modulation of NMDARs (Eisenman et al., 2003).
of MQ-182 and ample intracellular accumulation without
discernible plasma membrane enrichment.
To validate MQ-182 as an oxysterol analog, we assayed
physiological properties at NMDARs. We found that MQ-
182 behaves, similarly, to 24S-HC, a major brain cholesterol
metabolite, at NMDARs. Both MQ-182 and 24S-HC potently
potentiate NMDAR currents, increase the channel open
probability of the NMDAR, and exhibit slow reversibility.
Furthermore, MQ-182 reduces potentiation by SGE-201, another
synthetic oxysterol analog, but not PS, a sulfated steroid.
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FIGURE 9 | Effect of MQ-182 on sPSCs and mPSCs. (A,B) Effect on AMPAR ESPCs (A) and GABAAR IPSCs (B). (A) In 10 µM gabazine and 25 µM D-APV to
isolate AMPAR EPSCs, baseline sEPSCs were followed by 30 s pre-application of 10 µM MQ-182 and further recording. Because many EPSCs occurred in
burst-like clusters in which individual events could not be accurately discerned, currents were integrated to yield total negative-going charge. The total
charge of AMPAR EPSCs did not increase. The right plot shows effect of MQ-182 normalized to baseline for individual cells. The red symbol denotes the mean change.
(Continued)
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FIGURE 9 | Continued
(B) Hippocampal cultures were exposed to 1 µM NBQX and 25 µM D-APV to isolate GABAAR IPSCs and the MQ-182 application protocol was repeated. The total
charge of GABAAR IPSCs was increased. Asterisk represents a significant increase in total charge (p = 0.024, n = 8, one-sample t-test). (C,D) Selective potentiation
of GABAAR mIPSCs. AMPAR mEPSCs (C) were isolated with 10 µM gabazine, 25 µM D-APV, and 0.2 µM TTX. Neither the amplitude nor the frequency of the
mEPSCs were potentiated by MQ-182. GABAAR mIPSCs (D) were isolated with 1 µM NBQX, 25 µM D-APV, and 0.2 µM TTX. Both the amplitude and the
frequency of GABAAR mIPSCs were potentiated by 10 µM MQ-182. Left asterisk represents a significant increase in amplitude (p = 0.0011, n = 9, one-sample
t-test). Right asterisk represents a significant increase in frequency (p = 0.0034, n = 9, one-sample t-test). (E) Integrated total charge of GABAAR IPSCs was not
potentiated by 1 µM MQ-182. GABAAR IPSCs were isolated as in (B). Recording in the presence of 1 µM MQ-182 followed a 30 s application. Application of 1 µM
MQ-182 did not increase the total negative-going charge of GABAAR IPSCs (p = 0.49, n = 8, one-sample t-test).
FIGURE 10 | MQ-182 potentiates NMDAR sEPSCS. (A) In 10 µM gabazine and 1 µM NBQX to isolate NMDARs, baseline sEPSCs were followed by 30 s
pre-application of 1 µM MQ-182 and further recording. Because the majority of NMDAR sEPSCs did not occur in burst-like clusters, like GABAAR sIPSCs, individual
EPSCs could be detected with confidence. (B) Representative trace of an average waveform of individual EPSCs for an exemplar cell. (C) EPSC decays were fitted
with a bi-exponential function. Tau values weighted by the relative amplitudes of the components are plotted. The red symbols denote the mean decay time for each
condition. MQ-182 increased the decay time of NMDAR ESPCs. Asterisk represents potentiation (p = 0.018, n = 6, Student’s paired t-test). Amplitude of events was
not increased (-1.96 ± 5.92% increase, p = 0.71, n = 6, Student’s paired t-test). Frequency of events was also not increased (-2.65 ± 7.32% increase, p = 0.49,
n = 6, Student’s paired t-test).
Additional neurosteroid analogs may allow additional insight
into the structure–activity relationships of allosteric modulators.
The cellular fate of lipophilic neurosteroids and oxysterols is
not well understood, with different mechanisms proposed
for different oxysterols. For example, some oxysterols
accumulate by energy-dependent mechanisms (Peyrot
et al., 2014), while others accumulate passively (Jiang et al.,
2016). The distribution of steroid-like modulators is also
varied – some exhibit Golgi-selective accumulation (Jiang
et al., 2016), while others accumulate in other intracellular
compartments (Li et al., 2007) or the plasma membrane
(Laverty et al., 2017; Miller et al., 2017). Our results suggest
a passive mechanism of MQ-182 accumulation, because
cell viability was not required for uptake. Co-labeling also
suggested a rather indiscriminate intracellular distribution,
with failure of co-localization with either Golgi or endoplasmic
reticulum markers (Figures 6E,F). This may indicate that
lower aqueous concentrations are needed for potentiation, as
passive, hydrophobic interactions may promote a high local
membrane concentration but could also promote sequestration
in intracellular organelles (Chisari et al., 2010). Passive uptake
also implies non-specific accumulation in all cells, regardless
of expression of transporters or pumps required for active
uptake.
Slow reversibility seems to be a hallmark of oxysterol and
steroid modulation of NMDAR activity (Horak et al., 2004; Paul
et al., 2013). Slow reversibility is also a feature of neuroactive
steroids that modulate GABAARs (Shu et al., 2004). This
feature correlates with lipophilicity, consistent with membrane
partitioning. In the case of GABAergic neurosteroids, γ-CDX
promotes rapid offset of potentiation, suggesting that membrane-
associated steroid rapidly dissociates from the receptor into
the membrane, where it is accessible to γ-CDX. In the case
of MQ-182, we found that potentiation offset is insensitive to
γ-CDX. This suggests one of three possibilities: (1) that MQ-
182 accumulates in a membrane area inaccessible to γ-CDX, (2)
that MQ-182 exhibits slow dissociation from the NMDAR, or
3) that MQ-182 is not sequestered by γ-CDX. Because γ-CDX
diminishes potentiation when it is pre-mixed with MQ-182
(Figure 5D), γ-CDX effectively lowers the aqueous concentration
of MQ-182, presumably through complexing. Thus, we can
exclude the third possibility. We cannot totally exclude possibility
2. However, given that several other lipophilic modulators have
recently been shown to have membrane-facing binding sites
(Chen et al., 2012; Laverty et al., 2017), and other oxysterols
exhibit γ-CDX-sensitive potentiation (Shu et al., 2007), we favor
possibility 1, that the interaction of MQ-182 with the membrane
precludes access by γ-CDX.
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MQ-182’s diffuse pattern of accumulation led us to explore
off-target effects, and we recorded pooled sEPSCs and sIPSCs
from multi-neuron cultures. We observed that 10 µM MQ-182,
a saturating concentration at NMDARs, increased the frequency
of sPSCs. Because sPSCs are often driven by action potential
firing, we reasoned that disinhibition through a postsynaptic
effect on GABAARs might account for the sPSC frequency
increase. However, 10 µM MQ-182 failed to inhibit responses
to exogenous GABA, indicating that the increase in sPSCs
cannot be accounted for by postsynaptic disinhibition. Instead,
we found that mIPSC frequency was also increased. Because
action potentials are not involved in mIPSCs, we conclude that
an effect on presynaptic machinery accounts for the effect of high
MQ-182 concentrations on transmission. Our observation that
GABAAR mIPSCs increase in both amplitude and frequency is
unexpected, as an increase in amplitude is classically interpreted
as a postsynaptic effect, but MQ-182 fails to alter exogenous
GABAAR responses (Figure 8). To reconcile these observations,
we speculate that MQ-182 may foster multivesicular fusion,
leading to elevated synaptic GABA concentration and larger
mIPSCs. Although these results merit follow-up, it is important
to note that 10 µM MQ-182 is well above the EC50 of the
compound at NMDARs (1.2 nM). When we tested 1 µM
MQ-182, we did not observe an increase in the charge of
GABAAR sIPSCs, suggesting that MQ-182’s off-target effects are
not observed at concentrations closer to the EC50 for NMDAR
effects. A lower concentration of MQ-182 increased the decay
time constant of NMDAR sEPSCs without altering sIPSCs. These
results suggest that using MQ-182 at a low dose in vivo may
selectively modulate NMDARs. However, we anticipate the major
uses of MQ-182 will be in vitro, for cell biological and biochemical
studies in which concentration can be precisely controlled.
A feature of MQ-182 labeling is the retention of some non-
UV linked compound following fixation and in situ click labeling
(Figure 6). This behavior has also been observed for other alkyne-
labeled probes (Yang et al., 2010; Viertler et al., 2012; Peyrot et al.,
2014; Emnett et al., 2016). The factors resulting in this retention
are not clear at present, but qualitatively the distribution of
photo-linked compound appeared similar to that of non-photo-
linked compound.
In this study, we introduce a novel oxysterol analog that allows
tandem photolabeling and click chemistry. This strategy enabled
us to permanently label cellular analog accumulation, permitting
insight into mechanisms of cellular compartmentalization.
Further understanding of this class of compounds should aid in
the synthesis of new drugs and to new insights into the targets of
biologically active cholesterol metabolites.
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